doi: 10.1161/01.CIR.0000058861.82724.42
(Circulation. 2003;107:e9005.)
© 2003 American Heart Association, Inc.
Cardiovascular News
Circulation Newswriter
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Inflammatory Markers
This week’s issue of Circulation focuses on markers of inflammation and their importance in cardiovascular disease. Paul Ridker, MD, of Harvard Medical School in Boston, Mass, emphasizes in his study that C-reactive protein is an important factor in the development of the Metabolic Syndrome (Circulation. 2003;107:391–397).
The issue also includes the AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease from the American Heart Association and the US Centers for Disease Control and Prevention (Circulation. 2003;107:499–511).
In addition, this issue inaugurates Circulation’s new section, Mini-Review: Expert Opinions, which is designed to provide assistance to care providers of patients with cardiovascular disease and to stimulate future research on the topic. Dr Ridker’s review of inflammatory markers begins on page 363 of this new section and is followed by a review on page 370 by Circulation board member Edward Yeh, MD, and Circulation editor James T. Willerson, MD, both of the University of Texas Health Science at Houston. The two reviews are followed by an editorial comment by Dean Kereiakes, MD, of the Ohio Heart Health Center and Professor of Clinical Medicine at Ohio State University. Dr Kereiakes is editor of the new section.
An ENCORE Is Possible
Treatment with nifedipine improved coronary endothelial function in patients randomized to receive that treatment as part of the Evaluation of Nefedipine and Cerivastatin On the Recovery of Endothelial Function (ENCORE) study, according to a report in this week’s issue of Circulation (Circulation. 2003;107:422–428).
Writing on behalf of the ENCORE investigators, Thomas F.